Apoptosis and its significance in MDS: Controversies revisited

Leukemia Research

Volumn 23, Issue 9, 1999, Pages

  Yoshida, Yataro ^a   Mufti, Ghulam J ^b  

^a Division of Hematology   (Japan)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMIFOSTINE; CASPASE; CASPASE INHIBITOR; CIPROFLOXACIN; CYTOKINE; DEXAMETHASONE; ERYTHROPOIETIN; FAS LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; RETINOIC ACID;

APOPTOSIS; CELL CYCLE; FLOW CYTOMETRY; HUMAN; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW;

ANTIGENS, CD95; APOPTOSIS; CASPASES; CELL CYCLE; CLONE CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 0344849510     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00094-6     Document Type: Review

References (62)

1. Bennett J., Catovsky D., Daniel M., Flandrin G., Galton D., Gralnick H., Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51:1982;189.
2. Greenberg P., Cox C., Lebeau M.M., Fenaux P., Morel P., Sanz C., Sanz M., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Mufti G., Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89:1997;2079.
3. Yoshida Y. Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia. 7:1993;144.
4. Yoshida Y., Stephenson J., Mufti G.J. Myelodysplastic syndromes: from morphology to molecular biology. Part I. Classification, natural history and cell biology of myelodysplasia. Int. J. Hematol. 57:1993;87.
5. Yoshida Y., Anzai N., Kawabata H. Apoptosis in myelodysplasia: a paradox or paradigm. Leuk. Res. 19:1995;887.
6. Parker J.E., Mufti G.J. Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes. Br. J. Haematol. 101:1998;220.
7. Greenberg P.L. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Luek. Res. 22:1998;1123.
8. Clark D.M., Lampert I.A. Apoptosis is a common histopathological finding in myelodysplasia: the correlate of ineffective hematopoiesis. Leuk. Lymphoma. 2:1990;415.
9. Ohmori M., Ohmori S., Ueda Y., Yoshida Y., Okuma M. Ineffective hematopoiesis in the myelodysplastic syndromes (MDS) as studied by daily in situ observation of colony-cluster formation. Int. J. Cell Cloning. 9:1991;521.
10. Bogdanovic A.D., Trpinac D.P., Jancovic G.M., Bumbasirevic V.Z., Obdanovic M., Colovic M.D. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia. 11:1997;656.
11. Raza A., Gezer S., Mundle S., Gao X.Z., Alvi S., Borok R., Rifkin S., Iftikhar A., Shetty V., Parcharidou A., Loew J., Marcus B., Khan Z., Chaney C., Showel L., Gregory S., Preisler H. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 86:1996;268.
12. Anzai N., Kawabata H., Hirama T., Masutani H., Ohmori M., Yoshida Y., Okuma M. Marked apoptosis of human myelomonocytic cell line P39. Significance of cellular differentiation. Leukemia. 8:1994;446.
13. Lepelley P., Campergue L., Gradel N., Preudhomme C., Cosson A., Fenaux P. Is apoptosis a massive process in myelodysplastic syndromes? Brit. J. Haematol. 95:1996;368.
14. Hellström-Lindberg E., Kanter-Lewensohn L., Ost A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk. Res. 21:1997;415.
15. Bouscary D., De Vos J., Guesnu M., Jondeau K., Viguier F., Melle J., Picard F., Dreyfus F., Fontenay-Roupie M. Fas/apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia. 11:1997;839.
16. Kitagawa M., Yamaguchi S., Takahashi M., Tanizawa T., Hirokawa K., Kamiyama R. Localization of fas and fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia. 12:1998;486.
17. Rajapaksa R., Ginzton N., Rott L.S., Greenberg P.L. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood. 88:1996;4275.
18. Parker J.E., Fishlock K.L., Mijovic A., Czepulkowski B., Pagliuca A., Mufti G.J. Low-risk myelodysplastic syndromes is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. Br. J. Haematol. 103:1998;1075.
19. Ricciardi M.R., Petrucci M.T., Ariola C., Gregorj C., Mazzola R., Latagliata R., Petti M.C., Tafuri A. High levels of apoptosis characterize RAEB and are lost during leukemic transformation. Blood. 90(1):1997;520a.
20. Raza A., Mundle S., Shetty V., Alvi S., Chopra H., Span L., Parcharidou A., Dar S., Venugopal P., Borok R., Gezer S., Showel J., Loew J., Robin E., Rifkin S., Alston D., Hernandez B., Shah S., Kaiserthe H., Gregory S. Novel insight into the biology of myelodysplastic syndromes: excess apoptosis and the role of cytokines. Int. J. Hematol. 63:1996;265.
21. Davis R.E., Grenberg P.L. Bc1-2 expression by myeloid precursors in myelodysplastic syndromes: immunostaining of bone marrow biopsies. Leuk. Res. 22:1998;767.
22. Gersuk G.M., Yamaguchi M., Beckman C., Kiener P., Anderson J.E., Trout T., Loken M.R., Deeg H.J. A role for fas, fas-ligand and TNF-α in the dysregulation of hematopoiesis in myelodysplastic syndrome (MDS). Blood. 88:1996;639a.
23. Kitagawa M., Saito I., Kuwata T., Yoshida S., Yamaguchi S., Takahashi M., Tanizawa T., Kamiyama R., Hirokawa K. Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes. Leukemia. 11:1997;2049.
24. Raza A., Gezer S., Gregory S.A., Venugopal P., Kaiser H., Dong L.M., Span L., Hines C., Thomas R., Alvi S., Mundle S.D., Shetty V., Vorok R., Loew J., Reza S., Robin E.L., Rifkin S.D., Alston D., Hernandez B.M., Shah H., Hsu W.T., Dar S., Preisler H. Anti-cytokine therapy produces responses in patients with myelodysplastic syndromes (MDS). Blood. 88:1996;580a.
25. + myelodysplastic cells is associated with intracellular redox changes and elevated plasma necrosis factor-α concentration. Br. J. Haematol. 99:1997;624.
26. Verhof G.E., De Showwer P., Ceuppens J.L., Van Damme J., Goosens W., Boogaerts M.A. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia. 6:1992;1268.
27. Maurer A.B., Ganser A., Buhl R., Seipelt G., Ottomann O.G., Mentzel U., Geissler R.G., Hoelzer D. Restoration of impaired cytokine secretion from monocytes of patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3. Leukemia. 7:1993;1728.
28. Bowen D., Yancik S., Bennett L., Culligan D., Resser K. Serum stem cell factor concentration in patients with myelodysplastic syndromes. Br. J. Haematol. 85:1993;63.
29. Visani G., Zauli G., Tosi P., Fogli M., Cenacchi A., Finelli C., Gamberi B., Ottaviani E., Manfoni S., Tura S. Impairment of GM-CSF production in myelodysplastic sydromes. Br. J. Haematol. 84:1993;227.
30. Shetty S., Hussaini L., Broady-Robinson X., Gao S., Dar S., Mundle J., Cartlidge K., Bagai M., Showel C., Andrews A., Akhtar A., Ali B.Y., Mativi P., Venugopal H., Chopra S.B., Gregory S.A., Preisler H., Raza A. Suppression of tumor necrosis factor-alpha (TNF-α) induced apoptosis by Flt-3 ligand in myelodysplastic syndromes (MDS) and HL-60 cells. Blood. 90:1997;203a.
31. + human bone marrow cells is induced by interferon-γ and tumor necrosis a and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 85:1995;3183.
32. Mativi B.Y., Mundle S., Ali A., Bagai K., Venugosal P., Feldman G., Cartlidge J., Qawi H., Shetty V., Gregory S.A., Raza A. Fas/fas-L system could be one of the mediators of excessive apoptosis in myelodysplastic syndromes (MDS). Blood. 90:1997;202a.
33. Won J.H., Yu B.W., Hong D.S., Suh W.S., Jeon J.W., Baick S.H., Park H.S. The expression of the fas antigen and apoptosis in patients with myelodysplastic syndromes and its clinical relevance. Blood. 88:1996;95a.
34. Stahnke K., Hecker S., Kohne E., Debatin K.M. CD95 (Apo-1/fas)-mediated apoptosis in cytokine-activated hematopoietic cells. Exp. Hematol. 26:1998;844.
35. Preudohomme C., Vachee A., Lepelley P., Vanrumbeke M., Zandecki M., Quesnel B., Cosson A., Fenaux P. Inactivation of retinoblastoma gene appears to be very uncommon in myelodysplastic syndromes. Br. J. Haematol. 87:1994;61.
36. Lai J.L., Preudhomme C., Zandecki M., Vanrumbeke M., Lepelly P., Wattel E., Fenaux P. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion: an entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutation. Leukemia. 9:1995;370.
37. Jonveaux P., Fenaux P., Quiquandon L., Pignon J.M., Lai J.L., Loucheux-Lefebvre M.H., Goossens M., Bauters F., Berger R. Mutations in the p53 gene in myelodysplastic syndromes. Oncogene. 6:1991;2243.
38. Wattel E., Prudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I., Morel P., Fenaux P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 84:1994;3148.
39. Sugimoto K., Hirano N., Toyuoshima H., Chiba S., Mano H., Takaku F., Yazaki Y., Hirai H. Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood. 81:1993;3022.
40. Uchida T., Kinoshita T., Nagai H., Nakahara Y., Saito H., Hotta T., Murate T. Hypermethylation of the p15(INK4B) gene in myelodysplastic syndromes. Blood. 90:1997;1403.
41. INK4b in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 91:1998;2985.
42. Parker J.E., Fishlock K.L., Pagliuca A., Mufti G.L. The role of apoptosis, proliferation and amifostine in the myelodysplastic syndromes (MDS) and AML secondary to MDS. Blood. 1:1998;418a.
43. Ali A., Mundle D., Ragasa D., Reza S., Shetty V., Mativi B.Y., Cartlidge J., Azharuddin M., Hines C., Raza A. Sequential activation of caspases during spontaneous apoptosis of bone marrow cells in myelodysplasia. Blood. 90:1997;521a.
44. Kliche K.O., Clement J.H., Kunert C., Flicke H.J., Hoffken K. Increased caspase activity in myelodysplastic syndromes and secondary acute myeloid leukemia. Blood. 92(1):1998;419a.
45. Campos L., Sabido O., Viallet A., Piselli S., Guyotat D. Implication of ICE and CPP32 in the in vitro growth of committed progenitors from myelodysplastic syndromes. Blood. 90:1997;521a.
46. Silverman L.R., Zinzar S., Holland J.F. Biological consequences of stromal abnormalities in the myelodysplastic syndrome (MDS): its influence on the hematopoietic dysregulation. Leuk. Res. 21:1997;S20.
47. Aizawa S., Nakano M., Iwase O., Yaguchi M., Hiramoto M., Hoshi H., Nabeshima R., Shima D., Handa H., Toyama K. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation. Leuk. Res. 23:1999;239.
48. Okada M., Okamoto K., Saheki K., Fujimori Y., Takemoto Y., Kakishita E. Increased expression of fas antigen and apoptosis in patients with myelodysplastic syndromes. Blood. 90:1997;202a.
49. Kliche K.O., Andreef M. High expression of phosphatidylserine (PS) in MDS, secondary AML (sAML) and normal progenitors. Blood. 90:1997;202a.
50. - cells to undergo apoptosis in myelodysplastic marrows. Int J Hematol (in press).
51. Tsoplou P., Kourakli-Symeonidis A., Thanopoulou E., Orphanos V., Zoumbos N. Apoptosis in patients with myelodysplastic syndromes (MDS): differential involvement of marrow cells in early versus advanced cases and correlation with the expression of apoptosis-related genes. Blood. 90:1997;202a.
52. +. Blood. 88:1996;95a.
53. Philpott N.J., Scopes J., Marsh J.C.W., Gordon-Smith E.C., Gibson F.M. Increased apoptosis in aplastic anemia bone marrow progenitor cells: possible pathophysiologic significance. Exp. Hematol. 23:1995;1642.
54. Koh P.S., Hughes G.C., Faulkner G.R., Keeble W.W., Bagby R.C. The Fanconi anemia group C gene product modulates apoptotic response to tumor necrosis factor-α and fas ligand but does not suppress expression of receptors of the tumor necrosis factor receptor superfamily. Exp. Hematol. 27:1999;1.
55. Perdahl E.B., Naprstek B.L., Wallace W.C., Lipton J.M. Erythroid failure in Diamond-Blackfan anemia is characterized by apoptosis. Blood. 83:1994;645.
56. Yoshida Y., Anzai N., Kawabata H. Apoptosis in normal and neoplastic hematopoiesis. Crit. Rev. Oncology/Hematology. 24:1996;185.
57. 2 on in vitro apoptosis and proliferation in myelodysplastic (MDS) bone marrow. Blood. 90:1997;521a.
58. + cells and promote progenitor growth via polyamine-like effects. Blood. 90:1997;520a.
59. List A.F., Brassfield F., Heaton R., Glinsmann-Gibson B., Crook L., Taetle R., Capizzi R. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndromes. Blood. 90:1997;3364.
60. Moroni M., Porta C., Invernizzi R., Inzoli A., Bobbio-Pallavicini F., Bobbio-Pallavicini E. TUNEL evidence of reduced bone marrow cells apoptosis in a refractory anemia patient treated with amifostine. Br. J. Haematol. 104:1999;420.
61. Raza A., Qawi H., Nasser O.B., Dar S., Lisak L., Andric T., Ali S.I., Quadri M., Ahmed P., Venugopal P., Gezer S., Gregory S., Loew J., Robin E., Riflcin S. Cytopenias improve in response to amifostine/pentoxifylline/ciprofloxacin/dexamethazone (PCD) in patients with myelodysplastic syndromes (MDS). Blood. 92:1998;631a.
62. Cortelezzi A., Sarina B., Cattaneo C., Cristiani S., Silvestris I., Motta M., Ibatici A., Maiolo A.T. N-acetylcysteine and all-trans retinoic acid on hemopoiesis in myelodysplastic syndromes (MDS): effect on apoptosis and clonogenic potential. Blood. 92:1998;631a.